A sequential double blind cross-over trial of tocainide hydrochloride in tinnitus.

Abstract

A sequential double blind cross-over trial of tocainide hydrochloride, an oral analogue of lignocaine, is reported. The dosage of tocainide hydrochloride ranged from 200-600 mg daily. Of the 32 patients who completed the trial, 1 had complete relief and 2 had partial relief of their tinnitus whilst taking tocainide. An increased incidence of side-effects in patients taking tocainide was noted, in particular, headache, dizziness, nausea and skin rashes.

• Authors: A W Blayney, M S Phillips, A M Guy, B H Colman
• Journal: Clinical otolaryngology and allied sciences (Clin Otolaryngol Allied Sci) Vol. 10 Issue 2 Pg. 97-101 (Apr 1985) ISSN: 0307-7772 [Print] England
• PMID: 3928215 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)

Chemical References

• Tocainide
• Lidocaine

Topics

• Adult
• Aged
• Clinical Trials as Topic
• Dizziness (chemically induced)
• Double-Blind Method
• Headache (chemically induced)
• Humans
• Lidocaine (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
• Middle Aged
• Tinnitus (drug therapy)
• Tocainide